Basis: FMP quote price / unrounded FMP forward EPS in the trading currency, available after its recorded retrieval time. Source: stored company filings and market data; unavailable inputs remain N/A.
The forward PE ratio is 28.75 as of 2026-09-26T00:15:44.311Z.
Consensus retrieved: 2026-09-13T22:46:24.808Z. This records retrieval, including cache reads, rather than vendor publication. The calculation uses the separately dated price and estimate available at its as-of time.
Calculation as of: 2026-09-26T00:15:44.311Z.
Quote observation: 2026-09-25T20:00:03.000Z. Amounts in USD. The price header may show a later quote.
FMP input reference: a867f74022b929e80d197199fbfebc6630f0c88c819bafdecee0647af169585c
Forward PE Ratio (28.75) = Dated Quote Price ($86.29) / Consensus Forward EPS ($3.00)
FORWARD PE RATIO
28.75
SECTOR MEDIAN · HEALTHCARE
18.73
median of 76 covered companies
CURRENT VS SECTOR MEDIAN
+53.50%
vs the sector median at left
Edwards Lifesciences Corporation
Market Cap
$49.69B
Forward PE Ratio
28.75
| NAME | MARKET CAP | FORWARD PE RATIO |
|---|---|---|
| Edwards Lifesciences Corporation (EW) | $49.69B | 28.75 |
| Agilent Technologies, Inc. (A)vs › | $48.80B | 27.86 |
| Becton, Dickinson and Company (BDX)vs › | $50.65B | 14.51 |
| Humana Inc. (HUM)vs › | $47.81B | 43.49 |
| Cardinal Health, Inc. (CAH)vs › | $51.58B | 17.56 |
| Teva Pharmaceutical Industries Limited (TEVA)vs › | $45.64B | 19.72 |
| IQVIA Holdings Inc. (IQV)vs › | $44.50B | 20.85 |
| Waters Corporation (WAT)vs › | $42.57B | 29.75 |
| IDEXX Laboratories, Inc. (IDXX)vs › | $40.96B | 35.15 |
| Cencora, Inc. (COR)vs › | $59.71B | 17.17 |
Trailing P/E
49.6
reported TTM EPS
Forward P/E
28.8
consensus EPS · fiscal year ending 2026-12-31
The gap between the two multiples is the consensus growth expectation: analysts' forward EPS of $3.00 implies +72.4% EPS growth vs the reported trailing $1.74.
At the dated quote price of $86.29, each upcoming fiscal year's consensus EPS implies a different multiple — how quickly the price is "paid down" by expected earnings if the estimates hold.
| Fiscal year end | Consensus EPS | Estimate range | Analysts | Implied P/E |
|---|---|---|---|---|
| 2026-12-31 | $3.00 | $2.97 – $3.05 | 16 | 28.8x |
| 2027-12-31 | $3.39 | $3.29 – $3.46 | 16 | 25.5x |
| 2028-12-31 | $3.79 | $3.66 – $3.89 | 8 | 22.7x |
Source: FMP analyst consensus estimates, refreshed with the daily precompute. "n/m" = the consensus EPS is not positive, so a multiple is undefined. There is no forward P/E history chart here because charting one would require the estimates as they stood in the past, which we do not store — see the trailing P/E history for how the realized multiple has moved.
PE Ratio = Share Price / Diluted EPS (TTM)
The price-to-earnings ratio measures how much investors pay for each dollar of trailing earnings. A lower PE can indicate a cheaper valuation; a higher PE implies higher growth expectations.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
